Finerenone in Heart Failure-A Novel Therapeutic Approach

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2025 Jan 8

PMID 39769473

Authors

Amalie Holst-Hansen

Daniela Grimm

Markus Wehland

Affiliations

Soon will be listed here.

Abstract

This review will discuss heart failure, introduce a new drug finerenone, and discuss clinical studies with a focus on its effects on heart failure. Heart failure is a condition or syndrome characterized by an impairment of the pumping ability of the heart, thus no longer keeping up with the demands of the body. There are several types of heart failure; among them are heart failure with reduced ejection fraction, with mildly reduced ejection fraction and with preserved ejection fraction. Heart failure can be caused by several factors including lifestyle factors and diseases such as hypertension, type 2 diabetes mellitus and other cardiovascular diseases. Chronic kidney disease is also a risk factor of heart failure, as it leads to a state of inflammation that can impair the cardiovascular system over time. The novel nonsteroidal mineralocorticoid receptor antagonist finerenone antagonizes the mineralocorticoid receptor and thereby decreases the amount of fibrosis and inflammation that is observed in many heart failure patients. It shows an equal tissue distribution among heart and kidney, a high affinity and selectivity for the mineralocorticoid receptor and little risk of hyperkalemia and feminization. It also exhibits a reduction in the incidence of cardiovascular outcomes among patients with chronic kidney disease and type 2 diabetes mellitus. Therefore, finerenone has been proposed as a beneficial medication for reducing heart failure, especially in patients with diabetes and chronic kidney disease. Further studies are to be conducted to clarify the effects of finerenone alone and in combination with other drugs.

References

Ostrominski J, Aggarwal R, Claggett B, Kulac I, Desai A, Jhund P . Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure. J Card Fail. 2024; 30(9):1170-1174. DOI: 10.1016/j.cardfail.2024.04.015. View

Solomon S, Ostrominski J, Vaduganathan M, Claggett B, Jhund P, Desai A . Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2024; 26(6):1334-1346. DOI: 10.1002/ejhf.3266. View

Filippatos G, Anker S, Agarwal R, Pitt B, Ruilope L, Rossing P . Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2020; 143(6):540-552. PMC: 7864612. DOI: 10.1161/CIRCULATIONAHA.120.051898. View

Agarwal R, Ruilope L, Ruiz-Hurtado G, Haller H, Schmieder R, Anker S . Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2022; 41(2):295-302. PMC: 9799031. DOI: 10.1097/HJH.0000000000003330. View

Gonzalez-Blazquez R, Somoza B, Gil-Ortega M, Martin Ramos M, Ramiro-Cortijo D, Vega-Martin E . Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018; 9:1131. PMC: 6189469. DOI: 10.3389/fphar.2018.01131. View

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776. View

Pitt B, Anker S, Bohm M, Gheorghiade M, Kober L, Krum H . Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015; 17(2):224-32. DOI: 10.1002/ejhf.218. View

Jankowski J, Floege J, Fliser D, Bohm M, Marx N . Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021; 143(11):1157-1172. PMC: 7969169. DOI: 10.1161/CIRCULATIONAHA.120.050686. View

Bakris G, Agarwal R, Anker S, Pitt B, Ruilope L, Rossing P . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23):2219-2229. DOI: 10.1056/NEJMoa2025845. View

10.

Chimura M, Wang X, Jhund P, Henderson A, Claggett B, Desai A . Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2024; 10(1):59-70. PMC: 11571069. DOI: 10.1001/jamacardio.2024.4613. View

11.

Pitt B, Filippatos G, Agarwal R, Anker S, Bakris G, Rossing P . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021; 385(24):2252-2263. DOI: 10.1056/NEJMoa2110956. View

12.

Vaduganathan M, Claggett B, Desai A, Jhund P, Lam C, Senni M . Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2024; 10(2):176-181. PMC: 11581494. DOI: 10.1001/jamacardio.2024.3782. View

13.

Karakasis P, Patoulias D, Popovic D, Pamporis K, Theofilis P, Nasoufidou A . Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: a Bayesian and frequentist network meta-analysis of randomized trials. Curr Probl Cardiol. 2024; 49(9):102742. DOI: 10.1016/j.cpcardiol.2024.102742. View

14.

Alpert J, Haynes F, Dalen J, Dexter L . Experimental pulmonary embolism; effect on pulmonary blood volume and vascular compliance. Circulation. 1974; 49(1):152-7. DOI: 10.1161/01.cir.49.1.152. View

15.

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With.... Eur Heart J. 2021; 42(48):4901. DOI: 10.1093/eurheartj/ehab670. View

16.

Bauersachs J, Lother A . Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl (2011). 2022; 12(1):19-26. PMC: 9073241. DOI: 10.1016/j.kisu.2021.11.001. View

17.

Rossing P, Burgess E, Agarwal R, Anker S, Filippatos G, Pitt B . Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022; 45(4):888-897. PMC: 9271031. DOI: 10.2337/dc21-1944. View

18.

McGill J, Agarwal R, Anker S, Bakris G, Filippatos G, Pitt B . Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023; 25(6):1512-1522. DOI: 10.1111/dom.14999. View

19.

Solomon S, McMurray J, Vaduganathan M, Claggett B, Jhund P, Desai A . Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024; 391(16):1475-1485. DOI: 10.1056/NEJMoa2407107. View

20.

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View